Portal de Periódicos da CAPES

Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial

2019; European Respiratory Society; Volume: 55; Issue: 2 Linguagem: Inglês

10.1183/13993003.01157-2019

1399-3003

Jennifer A. Whitty, Jenny Rankin, Dina Visca, Vicky Tsipouri, Letizia Mori, Lisa Spencer, Huzaifa Adamali, Toby M. Maher, Nicholas S Hopkinson, Surinder S. Birring, Morag Farquhar, Athol U. Wells, Piersante Sestini, Elisabetta Renzoni,

Medical Imaging and Pathology Studies

Ambulatory oxygen may be cost-effective in improving quality of life in fibrotic lung disease. To be more conclusive, we need to understand societal willingness to pay for quality of life improvements and whether improvements are sustained. http://bit.ly/2pAiBJi